ENGN
enGene Holdings Inc. NASDAQ Listed Feb 1, 2022$1.80
+0.00%
vs $1.80
Mkt Cap $92.2M
52w Low $1.40
3.7% of range
52w High $12.25
50d MA $1.78
200d MA $6.21
P/E (TTM)
—
EV/EBITDA
—
P/B
0.6x
Debt/Equity
0.2x
ROE
-43.5%
P/FCF
-0.9x
RSI (14)
42.20
ATR (14)
$0.09
Beta
-0.05
50d MA
$1.78
200d MA
$6.21
Avg Volume
876.8K
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
7171 Rue Frederick Banting · Saint-Laurent H4S 1Z9 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | TNS | -0.48 | -0.43 | +10.4% | 1.77 | -1.7% | -1.1% | -0.6% | -1.1% | -1.7% | +1.2% | — |
| Mar 9, 2026 | TNS | -0.55 | -0.44 | +20.0% | 7.05 | -1.0% | -1.6% | -0.9% | +6.1% | -1.9% | +1.0% | — |
| Dec 22, 2025 | TNS | -0.57 | -0.73 | -28.8% | 8.77 | +0.0% | +5.1% | +2.5% | +0.5% | -4.8% | -1.0% | — |
| Sep 11, 2025 | TNS | -0.50 | -0.57 | -14.5% | 6.06 | +0.0% | -5.8% | +4.6% | +1.7% | +7.4% | +6.7% | — |
| Jun 12, 2025 | TNS | -0.50 | -0.51 | -2.6% | 3.25 | +0.9% | +2.5% | -0.6% | -1.8% | +1.2% | -4.3% | — |
| Mar 10, 2025 | TNS | -0.37 | -0.48 | -30.5% | 5.24 | +2.1% | -1.7% | +2.7% | +1.1% | +0.9% | -5.0% | — |
| Dec 19, 2024 | TNS | -0.40 | -0.34 | +14.1% | 5.96 | +9.7% | -2.2% | +2.2% | +6.0% | -2.8% | +4.6% | — |
| Sep 10, 2024 | TNS | -0.37 | -0.32 | +13.5% | 6.50 | -1.2% | +3.1% | -0.7% | +0.6% | +1.5% | +2.2% | — |
| Jun 14, 2024 | TNS | -0.26 | -0.38 | -46.2% | 9.00 | -3.9% | -3.9% | -3.4% | +4.2% | +3.3% | -9.7% | — |
| Mar 11, 2024 | TNS | -0.41 | -0.46 | -11.3% | 16.53 | -0.8% | +1.6% | -0.1% | -0.6% | +1.0% | +4.2% | — |
| Jan 29, 2024 | TNS | — | -2.64 | — | 8.07 | -0.0% | -7.1% | +4.5% | +7.7% | -8.2% | +3.1% | — |
| Jul 31, 2023 | TNS | — | -0.30 | — | — | — | — | — | — | — | — | — |
| Apr 30, 2023 | TNS | — | -0.33 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 18 | Morgan Stanley | Downgrade | Equal-Weight → Underweight | — | $1.74 | $1.75 | +0.6% | -1.1% | -1.7% | +1.2% | +2.3% | +1.1% |
| May 8 | Citizens | Downgrade | Mkt Outperform → Mkt Perform | — | $1.72 | $1.71 | -0.6% | -12.8% | -0.7% | -3.4% | +6.9% | +17.5% |
| May 8 | Wells Fargo | Downgrade | Overweight → Equal Weight | $2 | $1.72 | $1.71 | -0.6% | -12.8% | -0.7% | -3.4% | +6.9% | +17.5% |
| May 8 | Raymond James | Downgrade | Strong Buy → Outperform | $4 | $1.72 | $1.71 | -0.6% | -12.8% | -0.7% | -3.4% | +6.9% | +17.5% |
| May 8 | Piper Sandler | Downgrade | Overweight → Neutral | $4 | $1.72 | $1.71 | -0.6% | -12.8% | -0.7% | -3.4% | +6.9% | +17.5% |
| May 8 | Oppenheimer | Downgrade | Outperform → Perform | — | $1.72 | $1.71 | -0.6% | -12.8% | -0.7% | -3.4% | +6.9% | +17.5% |
| May 8 | Morgan Stanley | Downgrade | Overweight → Equal-Weight | — | $1.72 | $1.71 | -0.6% | -12.8% | -0.7% | -3.4% | +6.9% | +17.5% |
| May 8 | Leerink Partners | Downgrade | Outperform → Market Perform | $2 | $1.72 | $1.71 | -0.6% | -12.8% | -0.7% | -3.4% | +6.9% | +17.5% |
| May 8 | Guggenheim | Downgrade | Buy → Neutral | — | $1.72 | $1.71 | -0.6% | -12.8% | -0.7% | -3.4% | +6.9% | +17.5% |
| Mar 11 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.94 | $6.83 | -1.6% | -0.9% | +6.1% | -1.9% | +1.0% | +0.3% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.68 | $8.06 | -7.1% | -18.8% | -1.6% | -0.9% | +6.1% | -1.9% |
| Nov 12 | Citizens | Maintains | Market Outperform → Market Outperform | — | $8.82 | $9.69 | +9.9% | -1.6% | -2.9% | +1.2% | -5.5% | -14.6% |
| Nov 12 | UBS | Maintains | Neutral → Neutral | — | $8.82 | $9.69 | +9.9% | -1.6% | -2.9% | +1.2% | -5.5% | -14.6% |
| Nov 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $8.82 | $9.69 | +9.9% | -1.6% | -2.9% | +1.2% | -5.5% | -14.6% |
| Nov 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.82 | $9.69 | +9.9% | -1.6% | -2.9% | +1.2% | -5.5% | -14.6% |
| Sep 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $6.06 | $6.06 | +0.0% | -5.8% | +4.6% | +1.7% | +7.4% | +6.7% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.06 | $6.06 | +0.0% | -5.8% | +4.6% | +1.7% | +7.4% | +6.7% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.18 | $5.25 | +1.4% | +4.8% | +2.2% | +13.3% | -3.7% | -5.8% |
| Apr 29 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.99 | $3.98 | -0.3% | +0.3% | +3.5% | -9.7% | +2.1% | -3.7% |
| Mar 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $5.24 | $5.35 | +2.1% | -1.7% | +2.7% | +1.1% | +0.9% | -5.0% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.24 | $5.35 | +2.1% | -1.7% | +2.7% | +1.1% | +0.9% | -5.0% |
| Feb 14 | UBS | Downgrade | Buy → Neutral | — | $6.25 | $6.11 | -2.2% | -5.6% | +1.2% | +10.4% | -7.1% | +2.8% |
| Dec 23 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.83 | $6.49 | +11.3% | +2.2% | +6.0% | -2.8% | +4.6% | +5.1% |
| Dec 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.64 | $8.52 | -1.4% | +0.1% | -6.5% | -2.1% | -5.3% | -12.1% |
| Sep 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.41 | $6.95 | +8.4% | -3.3% | +0.8% | -12.0% | +10.0% | +9.1% |
| Sep 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $6.50 | $6.42 | -1.2% | +3.1% | -0.7% | +0.6% | +1.5% | +2.2% |
No insider trades available.
8-K · 5.02
!!! Very High
enGene Holdings Inc. -- 8-K 5.02: Executive Change
Jul 16
8-K · 2.02
!! High
enGene Holdings Inc. -- 8-K 2.02: Earnings Results
enGene Holdings reported quarterly earnings results, with detailed financial performance available in the furnished press release exhibit.
Jun 15
8-K
enGene Holdings Inc. -- 8-K Filing
Jun 10
8-K · 8.01
!! High
enGene Holdings Inc. -- 8-K 8.01: Material Event / Announcement
enGene Holdings reported interim clinical data from its Phase 2 LEGEND trial of detalimogene, potentially advancing the gene therapy candidate toward regulatory milestones.
May 7
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
Engenuity changed its company name, which may signal a strategic pivot or rebranding effort that could affect market perception and investor recognition of the stock.
Apr 9
8-K · 1.01
! Medium
enGene Therapeutics Inc. -- 8-K 1.01: Equity Issuance
enGene Therapeutics (ENGN) entered an equity issuance agreement with Leerink Partners LLC, likely a registered direct offering that will dilute existing shareholders while raising capital for operations.
Mar 9
8-K
enGene Therapeutics Inc. -- 8-K Filing
enGene Therapeutics announced Q1 2026 results and expects to present updated data from its LEGEND trial for bladder cancer treatment at an upcoming spring medical conference.
Mar 9
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Avantis U.S. Small Cap Equity ETF | 32,565 | $329K | Feb 2026 |
| 2 | Virtus LifeSci Biotech Clinical Trials ETF | 33,300 | $317K | Jan 2026 |
| 3 | Small Cap Core Fund | 8,938 | $61K | Mar 2026 |
| 4 | Avantis U.S. Small Cap Equity Fund | 5,902 | $60K | Feb 2026 |
| 5 | Avantis U.S. Equity Fund | 1,125 | $11K | Feb 2026 |
Valuation
Market Cap
$92.2M
Enterprise Value
-$86.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.06x
P/B
0.55x
P/S
—
P/FCF
-0.91x
EV/EBITDA
—
Shares Out
51.1M
Financials (TTM)
Revenue
$0
Net Income
-$66.4M
EBITDA
-$125.9M
Free Cash Flow
-$100.7M
Op Cash Flow
-$99.2M
EPS Basic
$-2.29
EPS Diluted
$-1.32
EPS Forward
$-1.97
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$221.5M
Total Liab.
$53.8M
Total Equity
$167.7M
Cash
$193.8M
LT Debt
$15.3M
Book Value/Sh
$3.28
Debt/Equity
0.19x
Current Ratio
6.30
Quick Ratio
6.30
Returns & Growth
ROE
-43.5%
ROA
-36.3%
ROIC
-61.7%
Rev Growth YoY
+0.0%
EPS Growth YoY
-56.9%
Price Returns
2W
-1.1%
1M
-3.2%
3M
+20.0%
6M
-81.2%
12M
-51.1%
Technicals
52W High
$12.25
52W Low
$1.40
50d MA
$1.78
200d MA
$6.21
RSI (14)
42.20
ATR (14)
$0.09
Beta
-0.05
Avg Volume
877K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
12
Ex-Div Date
Aug 3, 2015
Analyst Price Targets
Consensus
$24.60
High
$33.00
Low
$10.00
Median
$27.00
Data updated apr 25, 2026 7:09am
· Source: financialmodelingprep.com